Nestle pulls out of bid to buy Merck’s consumer health business
Category: #health  By Dhananjay Punekar  Date: 2018-02-06
  • share
  • Twitter
  • Google Plus
  • Facebook
  • LinkedIn

Nestle pulls out of bid to buy Merck’s consumer health business

Nestle S.A. has reportedly withdrawn from its bid to buy out the consumer health business of Merck KGaA, the renowned manufacturer of Seven Seas Vitamins. Sources state that Nestle pulled out of the negotiation process with Merck post the supposed demand of nearly USD 4.99 billion that Merck put forward. Earlier in 2017, some of the key officials of Merck had made an announcement to sell the firm’s consumer healthcare division worth nearly USD 1 billion for funding its research activities to develop new drugs. Apparently, other pharma firms such as Pfizer have also displayed their interest in the purchase of the Merck’s healthcare unit.

Post discussions about Nestle entering a joint venture with Merck, speculations about Nestle being a buyer of Merck’s consumer health segment were being made across the pharma circles. However, one of the key sources claimed that the talks failed to yield any positive outcomes, since Nestle’s investors had been discouraging the firm to purchase Merck’s business. As per another reliable source, the deal had resulted in a failure on the grounds that Nestle did not agree with Merck on the price, which Merck estimated 20 times higher than the core valuation of its consumer healthcare segment.

Consumer health, as on today, is one of the latest emerging sectors, inclusive of over-the-counter medicines, condoms, sports nutrition, and vitamins. Records provide evidence to the fact that perpetually massive deals have taken place across the consumer healthcare industry in recent years, with the geriatric population and the health-conscious consumer base fueling the market demand. Nestle also seemed to be traversing on similar lines of manufacturing healthy and nutritious food & beverage products. On these grounds, the firm may have put forth a proposal to acquire the consumer health business of Merck in November last year, state experts. Despite being shortlisted by Merck to submit its final bid this year however, Nestle seems to have finalized its exit from the bid, driven by price constraints.



About Author

Dhananjay Punekar

Email: dhananjay.p@news.marketsizeforecasters.com   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...